Detail of "134457-28-6"
- CAS Number:
- 134457-28-6
- Name:
D-Alaninamide,N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-[(3-amino-1H-1,2,4-triazol-5-yl)amino]-L-phenylalanyl-4-[(3-amino-1H-1,2,4-triazol-5-yl)amino]-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-
- Molecular Structure:
![Molecular Structure of 134457-28-6 (D-Alaninamide,N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-[(3-amino-1H-1,2,4-triazol-5-yl)amino]-L-phenylalanyl-4-[(3-amino-1H-1,2,4-triazol-5-yl)amino]-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-)](http://www.lookchem.com/300w/2010/0618/134457-28-6.jpg)
- Formula:
- C80H102 Cl N23 O12
- Molecular Weight:
- 1613.2658
- Synonyms:
- D-Alaninamide,N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-[(5-amino-1H-1,2,4-triazol-3-yl)amino]-L-phenylalanyl-4-[(5-amino-1H-1,2,4-triazol-3-yl)amino]-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-(9CI); 22: PN: WO2007012430 SEQID: 24 claimed protein; Azaline B; Prazarelix;RWJ 47428-099
- Density:
- 1.348g/cm3
- Boiling Point:
- °Cat760mmHg
- Flash Point:
- °C
D-Alaninamide,N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-[(3-amino-1H-1,2,4-triazol-5-yl)amino]-L-phenylalanyl-4-[(3-amino-1H-1,2,4-triazol-5-yl)amino]-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-
Famous Chemical Enterprises
-
Livzon -
Total -
Shell -
Dupont -
Exxonmobil -
Akzonobel -
Basf -
Bayer -
BP
Please post your buying leads,so that our qualified suppliers
will soon contact you!
*Required Fields
Reference
- Method for induction and enhancement of apoptosis in tumor cells using GnRH II antagonists
- All Rights Reserved. Method for induction and enhancement of apoptosis in tumor cells using GnRH II antagonists. Gruendker, Carsten; Guenthert, Andreas R.; Emons, Guenter ( Georg-August-Universitaet-Goettingen, Germany). PCT Int. Appl. WO 2007012430 A1 1 Feb 2007, 49pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. APPLICATION: WO 2006-EP7153 20 Jul 2006. PRIORITY: US 2005-702283P 26 Jul 2005; US 2005-739424P 25 Nov 2005. DOCUMENT TYPE: Patent CA Section: 2 (Mammalian Hormones) Section cross-reference(s): 1 The present invention relates to methods for inducing and enhancing apoptosis in pathogenic cells. In particular, the present invention relates to the use of GnRH II antagonists for inducing and enhancing apoptosis of specific types of tumor cells, i.e. There are some commonly used reagents like 135215-95-1 in this article. breast cancer and malignant melanoma as well as gynecol. cancers like endometrial or ovarian cancer, expressing the GnRH II receptor as well as to methods relating thereto. In addn., new GnRH II antagonists are provided. .